New Ryan Field Deal a Positive Signal, But Core Risks Remain Intact

What happened

Evolv announced that its AI-powered Evolv Express has been selected as the official fan screening provider for Northwestern University’s new Ryan Field after a rigorous evaluation. This marks a high-profile win in the college sports market and reinforces the company’s presence in large venues. However, the deal does not materially change the investment thesis: management has guided for 2026 revenue growth of just 11–13%, ARR growth of ~20%, and subscription margins remain under pressure due to hardware disposals and field service costs. Legal uncertainties, including the FTC order and securities class actions, continue to overhang, while internal control weaknesses remain unremediated. The stock trades at a premium valuation with no GAAP earnings or free cash flow, and this win, while encouraging, is insufficient to offset the broader risks.

Implication

The deal underscores Evolv’s ability to win high-profile venue contracts, which could support long-term ARR growth if replicated at scale. However, it does not address the company’s decelerating growth profile, gross margin headwinds, or pending legal and regulatory issues that pose significant downside risk. Investors should view the stock as a trading hold rather than a fresh long until the company demonstrates sustainable GAAP profitability, resolution of legal overhangs, and consistent free cash flow generation. The current valuation already embeds optimistic assumptions; any disappointment on 2026 guidance or legal settlements could trigger multiple compression. We maintain our base case value of $7.00 and would wait for a pullback toward $5.50 before considering new positions.

Thesis delta

The Ryan Field win is a positive demand signal but does not shift our core concerns: revenue growth is decelerating, subscription margins are under pressure, and legal/regulatory overhangs persist. The investment thesis remains unchanged, and we maintain our POTENTIAL SELL rating.